ProCE Banner Activity

2022 ESGO Congress: Experts Discuss HRD Testing, PARP Inhibitors in Recurrent Ovarian Cancer, and QoL in Nonepithelial Ovarian Cancer

Clinical Thought
In this commentary, experts discuss studies from the 2022 ESGO Congress on emerging HRD assays in Europe, PARP inhibitor use in recurrent ovarian cancer, and quality of life in rare nonepithelial ovarian cancer after chemotherapy.

Released: December 02, 2022

Share

Faculty

Prof Isabelle Ray-Coquard

Prof Isabelle Ray-Coquard, MD, PhD

Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
Lyon, France

Ignace Vergote

Ignace Vergote, MD, PhD

Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven Belgium

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

GlaxoSmithKline

Karyopharm Therapeutics Inc

Merck Sharp & Dohme Corp

Faculty Disclosure

Primary Author

Prof Isabelle Ray-Coquard, MD, PhD

Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
Lyon, France

Prof Isabelle Ray-Coquard, MD, PhD: consultant/advisor/speaker: AstraZeneca, Clovis, GlaxoSmithKline, MSD.

Ignace Vergote, MD, PhD

Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven Belgium

Ignace Vergote, MD, PhD: consultant/advisor/speaker: Agenus, Akesobio, AstraZeneca, Bristol-Myers Squibb, Deciphera, Eisai, Elevar Therapeutics, Exelixis, F. Hoffmann-La Roche, Genmab, GlaxoSmithKline, Immunogen, Jazz, Karyopharm, Mersana, MSD, Novocure, Novartis, Oncoinvent, OncXerna, Regeneron, Sanofi, Seagen, Sotio, Verastem Oncology, Zentalis; researcher: Amgen, Roche, Oncoinvent AS.